HLB Co., Ltd. (028300.KQ)
KRW 70500.0
(-1.26%)
KRW 70500.0
(-1.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -125.02 Billion KRW | -55.36% |
| 2022 | -74.66 Billion KRW | 25.21% |
| 2021 | -99.83 Billion KRW | -9.33% |
| 2020 | -91.31 Billion KRW | -89.95% |
| 2019 | -48.07 Billion KRW | -63.8% |
| 2018 | -29.34 Billion KRW | -15.59% |
| 2017 | -25.39 Billion KRW | -8.94% |
| 2016 | -23.3 Billion KRW | -140.14% |
| 2015 | -9.7 Billion KRW | -1625.66% |
| 2014 | 636.13 Million KRW | 113.0% |
| 2013 | -4.89 Billion KRW | -29.9% |
| 2012 | -3.76 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -37.47 Billion KRW | 0.15% |
| 2024 Q1 | -35.78 Billion KRW | -41.86% |
| 2023 Q4 | -25.22 Billion KRW | 14.36% |
| 2023 Q2 | -33.51 Billion KRW | -20.58% |
| 2023 Q1 | -27.79 Billion KRW | -55.2% |
| 2023 Q3 | -29.45 Billion KRW | 12.11% |
| 2023 FY | -115.99 Billion KRW | -55.36% |
| 2022 Q3 | -36.66 Billion KRW | -169.7% |
| 2022 Q4 | -17.91 Billion KRW | 51.15% |
| 2022 Q2 | -13.59 Billion KRW | -109.16% |
| 2022 Q1 | -6.49 Billion KRW | 81.97% |
| 2022 FY | -74.66 Billion KRW | 25.21% |
| 2021 Q2 | -21 Billion KRW | -11.96% |
| 2021 Q4 | -36.03 Billion KRW | -49.98% |
| 2021 Q3 | -24.02 Billion KRW | -14.37% |
| 2021 FY | -99.83 Billion KRW | -9.33% |
| 2021 Q1 | -18.76 Billion KRW | 26.76% |
| 2020 Q4 | -25.61 Billion KRW | -28.58% |
| 2020 FY | -91.31 Billion KRW | -89.95% |
| 2020 Q2 | -39.53 Billion KRW | -534.51% |
| 2020 Q1 | -6.23 Billion KRW | 53.45% |
| 2020 Q3 | -19.92 Billion KRW | 49.61% |
| 2019 Q2 | -11.6 Billion KRW | -16.09% |
| 2019 FY | -48.07 Billion KRW | -63.8% |
| 2019 Q4 | -13.38 Billion KRW | -0.8% |
| 2019 Q3 | -13.27 Billion KRW | -14.39% |
| 2019 Q1 | -10 Billion KRW | 25.84% |
| 2018 Q4 | -13.48 Billion KRW | -129.05% |
| 2018 FY | -29.34 Billion KRW | -15.59% |
| 2018 Q2 | -4.69 Billion KRW | 10.93% |
| 2018 Q1 | -5.27 Billion KRW | 56.64% |
| 2018 Q3 | -5.88 Billion KRW | -25.29% |
| 2017 Q1 | -3.7 Billion KRW | 71.53% |
| 2017 FY | -25.39 Billion KRW | -8.94% |
| 2017 Q4 | -12.16 Billion KRW | -156.48% |
| 2017 Q3 | -4.74 Billion KRW | 0.65% |
| 2017 Q2 | -4.77 Billion KRW | -28.94% |
| 2016 FY | -23.3 Billion KRW | -140.14% |
| 2016 Q4 | -13 Billion KRW | -124.21% |
| 2016 Q3 | -5.8 Billion KRW | -86.34% |
| 2016 Q2 | -3.11 Billion KRW | -125.51% |
| 2016 Q1 | -1.38 Billion KRW | 74.97% |
| 2015 Q1 | -965.72 Million KRW | -457.52% |
| 2015 Q4 | -5.51 Billion KRW | -339.03% |
| 2015 Q3 | -1.25 Billion KRW | 34.45% |
| 2015 Q2 | -1.91 Billion KRW | -98.51% |
| 2015 FY | -9.7 Billion KRW | -1625.66% |
| 2014 Q2 | -757.89 Million KRW | -239.08% |
| 2014 Q4 | 270.11 Million KRW | -53.35% |
| 2014 Q1 | 544.94 Million KRW | 118.21% |
| 2014 FY | 636.13 Million KRW | 113.0% |
| 2014 Q3 | 578.96 Million KRW | 176.39% |
| 2013 Q1 | -1.41 Billion KRW | 39.91% |
| 2013 Q3 | 798.23 Million KRW | 161.97% |
| 2013 FY | -4.89 Billion KRW | -29.9% |
| 2013 Q4 | -2.99 Billion KRW | -474.83% |
| 2013 Q2 | -1.28 Billion KRW | 8.69% |
| 2012 Q4 | -2.34 Billion KRW | -194.74% |
| 2012 FY | -3.76 Billion KRW | 0.0% |
| 2012 Q3 | -796.56 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | -3705.975% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 12095.506% |
| Bioneer Corporation | 791.75 Million KRW | 15890.88% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | -2364.104% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | -397.498% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | -304.441% |
| Helixmith Co., Ltd | -35.24 Billion KRW | -254.726% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | -1226.496% |
| Medy-Tox Inc. | 17.32 Billion KRW | 821.755% |
| Peptron, Inc. | -15.6 Billion KRW | -701.291% |
| Amicogen, Inc. | 2.05 Billion KRW | 6180.553% |
| Genexine, Inc. | -41.24 Billion KRW | -203.157% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | -1337.023% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | -54.691% |
| ALTEOGEN Inc. | -9.73 Billion KRW | -1184.038% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 224.011% |
| SillaJen, Inc. | -21.34 Billion KRW | -485.71% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 4847.224% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | -587.503% |
| Genomictree Inc. | -17.3 Billion KRW | -622.541% |
| MedPacto, Inc. | -28.75 Billion KRW | -334.837% |
| D&D Pharmatech | -13.48 Billion KRW | -827.053% |
| EASY BIO,Inc. | 20.63 Billion KRW | 705.998% |
| GI Innovation, Inc. | -55.6 Billion KRW | -124.85% |